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Abstract
Health care has had to adapt rapidly to COVID-19, and this in turn has highlighted a pressing 
need for tools to facilitate remote visits and monitoring. Digital health technology, including 
body-worn devices, offers a solution using digital outcomes to measure and monitor disease 
status and provide outcomes meaningful to both patients and health care professionals. Re-
mote monitoring of physical mobility is a prime example, because mobility is among the most 
advanced modalities that can be assessed digitally and remotely. Loss of mobility is also an 
important feature of many health conditions, providing a read-out of health as well as a target 
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for intervention. Real-world, continuous digital measures of mobility (digital mobility out-
comes or DMOs) provide an opportunity for novel insights into health care conditions com-
plementing existing mobility measures. Accepted and approved DMOs are not yet widely 
available. The need for large collaborative efforts to tackle the critical steps to adoption is 
widely recognised. Mobilise-D is an example. It is a multidisciplinary consortium of 34 institu-
tions from academia and industry funded through the European Innovative Medicines Initia-
tive 2 Joint Undertaking. Members of Mobilise-D are collaborating to address the critical steps 
for DMOs to be adopted in clinical trials and ultimately health care. To achieve this, the con-
sortium has developed a roadmap to inform the development, validation and approval of 
DMOs in Parkinson’s disease, multiple sclerosis, chronic obstructive pulmonary disease and 
recovery from proximal femoral fracture. Here we aim to describe the proposed approach and 
provide a high-level view of the ongoing and planned work of the Mobilise-D consortium. 
Ultimately, Mobilise-D aims to stimulate widespread adoption of DMOs through the provision 
of device agnostic software, standards and robust validation in order to bring digital out-
comes from concept to use in clinical trials and health care. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Physical mobility is important. In fact, it is fundamental to life. Most of us take it for 
granted and never experience the consequences of immobility through ill health. COVID-19 
however has given us a sharp reminder of how important it is. The consequence of immobility 
– imposed externally through lockdown rather than internally by disease – is being revealed 
layer by layer at a personal and societal level, starting from the experience of restricted 
mobility and freedom, to the evolving impact on physical and mental health. The effects of 
COVID-19 are being felt disproportionately among older adults especially those with chronic 
ill health and multimorbidity [1, 2]. 
Health care has had to rapidly adapt to the pandemic with virtual clinics the “new normal” 
thanks to removal of barriers previously seen as insurmountable (data security, privacy, data 
breaches, patient acceptability, insurance coverage). Clinical research is facing similar chal-
lenges requiring rapid protocol and study delivery changes to ensure viability. The tools to 
facilitate remote visits and monitoring have never been more necessary. Digital health tech-
nology, including body-worn devices, offers a way forward by using digital outcomes to 
measure and monitor disease status and clinical outcomes meaningful to patients and health 
care professionals.
Remote monitoring of physical mobility is a prime example of what the future may look 
like, because mobility is among the most advanced modalities being assessed digitally and 
remotely. Loss of mobility is also an important feature of many health conditions, providing 
a read-out of health as well as a target for intervention [3, 4]. Real-world digital measures of 
mobility are therefore an area of promise for remote monitoring of health care conditions. In 
the last decade, advances in sensor technology have led to sensors that are able to record 
continuously for longer periods of time (weeks and months) and include multiple capabil-
ities. This opens the opportunity to extend the scope of mobility measurement to remotely 
and continuously capture discrete, relevant and ecologically valid mobility characteristics 
(such as real-world walking speed and life space). This digital approach to mobility assessment 
allows measurement to be performed anywhere and anytime providing an inclusive approach 
for patients. 
Although digital mobility assessment with wearable sensors offers a solution for remote 
monitoring of digital mobility outcomes, widely accepted tools are not yet available [5]. The 
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use of digital health technologies in clinical trials and ultimately health care poses significant 
challenges because of the multiple types of expertise (e.g., technical, clinical and regulatory) 
and steps (including both technical and clinical validation) required to deliver the evidence 
needed for adoption. Large collaborative consortia are recognised as an essential part of an 
overall strategy to develop and adopt digital health technologies and digital biomarkers in 
clinical trials [6]. 
Mobilise-D (Connecting digital mobility assessment to clinical outcomes for regulatory 
and clinical endorsement, www.mobilise-d.eu) is an example of one of the leading efforts 
aiming to deliver a solution for remote digital assessment of mobility. Mobilise-D is a public-
private partnership funded by the European Innovative Medicines Initiative 2 Joint Under-
taking. The Mobilise-D consortium includes 34 international research partners based at 
leading universities and some of the world’s largest pharmaceutical and technical companies. 
The overarching objective of Mobilise-D is to obtain regulatory approval for digital mobility 
outcomes in a variety of disease states – Parkinson’s disease (PD), chronic obstructive 
pulmonary disease (COPD), multiple sclerosis (MS) and recovery from proximal femoral 
fracture (PFF). The consortium will carry out a 5-year programme of activity (which 
commenced in April 2019) towards this objective. Importantly, this work takes place in a 
precompetitive context which is critical for success. A guiding principle of the collective 
efforts of the consortium is transparency aided by ongoing and regular interaction with 
external stakeholders. To ensure an enduring legacy, data will be accessible through a digital 
data biobank, and algorithms will be developed in an agnostic and fully documented manner 
for the wider benefit of developers.
Aims
In this paper, we aim to share the strategy developed and adopted by the Mobilise-D 
consortium and provide a high-level view of the ongoing work of Mobilise-D. We share the 
roadmap used to inform the development, validation and approval of digital mobility outcomes 
(DMOs), identify the challenges and provide an overview of the critical steps to bring digital 
biomarkers from conception to adoption.
Challenges to Adoption of DMOs
For digital health technologies and DMOs to be adopted, considerable multidisciplinary 
efforts are needed [6]. Important contributions have been made to bring stakeholders onto 
the same page, e.g. harmonisation of terms for biomarkers and end points [7], guidelines for 
development of novel digital end points [8, 9], frameworks for validation and primers [10–
12], and guidelines for interactions with regulators [13–15]. However, the challenge for 
anyone aiming to deliver digital tools approved for use in research and ultimately clinical 
practice is to bring these recommendations together in one seamless roadmap from inception 
to adoption. The Mobilise-D consortium aims to learn from and adopt these best practices 
whilst innovating in this space – leading with development of standards, disease and hardware 
agnostic approaches, open access tools and databases amongst other things. Technical and 
clinical validation, evaluation of acceptability and stakeholder engagement are undertaken 
within a multidisciplinary framework of collaboration and transparency. Figure 1 sets out the 
critical steps towards adoption. Throughout, embedded stakeholder engagement, external 
scientific advisory input and patient and public involvement will enrich the work of the 
Mobilise-D consortium. 
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Critical Steps in Mobilise-D to Bring Validated DMOs to Regulatory Approval
The following section describes the challenges and critical steps to achieve the objectives 
of the Mobilise-D consortium (summarised in Fig. 1). For clarity, a DMO is defined as a mobility 
outcome quantified from a wearable device (inertial measurement unit – IMU), using algo-
rithms to extract specific mobility features of interest. In Mobilise-D, we are specifically inter-
ested in DMOs collected continuously during everyday walking activities. We adopt a compre-
hensive approach to quantify DMOs harmonised across our cohorts (Table 1). Systematic 
reviews of the literature (in progress) will provide supporting evidence for these DMOs [16]. 
For simplicity we use the term DMO to be inclusive, because the evidence to identify the 
optimal measure is a key part of our ongoing validation studies and reviews. Walking speed 
is used as an example of a measure for illustrative purposes because of extensive work with 
this outcome under controlled conditions. However, the Mobilise-D consortium will not limit 
validation to a single DMO. 
Approved
 Verification of device accuracy
 Validation of software for range 
of digital mobility outcomes 
(older adults, PD, MS, COPD, 
PFF, CHF)
 Acceptability – human factors
 Standards published – device,
algorithm
 Data availability   
 Mobility performance
 Continuous and real-world
 Demonstrate DMOs monitor
and predict health outcomes
 Global and cohort-specific DMOs
 Standards and protocols for data
collection published
 Data availability   
 Digital mobility biomarkers
approved for use in clinical trials
 Concept of use for multiple
cohorts








(5) Robust digital data management platform, data security and ethics, digital mobility biobank
(6) Stakeholder engagement (patient and public; industry; scientific; clinical)





Fig. 1. The Mobilise-D roadmap. The critical steps of Mobilise-D from concept to adoption and their support-
ing work streams are illustrated and identified numerically. The anticipated outputs are described in the 
boxes for each critical step. The numbers correspond to the sections in the text “Critical steps in Mobilise-D 
to bring validated DMOs to regulatory approval.” DMO, digital mobility outcome; PD, Parkinson’s disease; MS, 
multiple sclerosis; COPD, chronic obstructive pulmonary disease; PFF, proximal femoral fracture; CHF, con-
gestive heart failure.
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Mobility – Is It a Global Concept of Interest?
Mobility is a term that describes the ability to move about in the home and community. 
Ageing and most chronic diseases make people physically weaker, less mobile and therefore 
less able to live independently. Walking is the commonest and most functionally relevant 
aspect of mobility affected by ageing and multiple chronic diseases. Walking requires cardio-
vascular, pulmonary and musculoskeletal systems as well as widespread brain networks for 
effective performance [17]. Changes in any of these systems because of ageing and/or disease 
are reflected in walking performance. As such, walking speed is often considered the 6th vital 
sign of health [4] and represents an appropriate mobility measure for multiple populations. 
Strong evidence that mobility outcomes, such as walking speed and walking activity, predict 
morbidity, mortality, falls, cognitive impairment and disability [3, 18–20] provide further 
support for this contention. Mobility is therefore an important target for interventions across 
many diseases and is also highly relevant because it is an important read-out of the integrity 
of the brain and body. 
Despite this, inconsistent testing procedures and wide variations in so-called “norms” 
have prevented walking outcomes from being widely adopted. Current methods to measure 
mobility have some important limitations. Mobility is often estimated using brief functional 
tests that have limited validity. For example, they can lead patients to over-perform in a short 
assessment. Furthermore, patients are required to attend a centre for assessment which 
reduces generalisability of study findings and overall quality of care. Better ways to detect 
and objectively measure mobility in real-world settings (and eventually capture early mobility 
problems) are needed that in turn will help accelerate development and testing of new treat-
ments and lead to better tools for use in health care. 
In our cohorts, mobility is estimated using brief functional tests such as the 6-min walking 
test [21], the 10-metre walking test [22], the 25-foot walk [23], the “timed-up-and-go test” 
[24] or the 4-metre walk test as part of the Short Physical Performance Battery  [25]. Conse-
quently, walking assessment is inconsistent within and between diseases, precluding a 
harmonised approach to the measurement and understanding of mobility disability. A further 
shortcoming of these tests is that they estimate capacity for mobility and therefore lack 
ecological validity; the fact that patients can move, does not necessarily mean that they do so 
in their day-to-day life [26–29]. There is therefore a strong argument for mobility assessment 
to reflect the real-world because this represents what a patient does do, not what they can 
do. 
Table 1. Examples of digital mobility outcome measures selected for validation in Parkinson’s disease, 
multiple sclerosis, chronic obstructive pulmonary disease and proximal femoral fracture recovery
Average walking speed over a rectilinear walking bout (m/s)
Metrics extracted for each walking bout
– Cadence (steps/min) 
– Step/stride time (s) 
– Swing/stance time (s)
– Stride length (m)
– Turn duration (s)
– Turn angle (degrees)
– Turn velocity (mean and peak) (degrees/s)
Metrics extracted from all walking bouts (at daily level)
– Volume of walking: number, length and duration of walking bouts
– Number of steps per day, walking time, walking/movement intensity 
18Digit Biomark 2020;4(suppl 1):13–27
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The Mobilise-D consortium describes mobility using 3 distinct constructs: 
 • Mobility capacity (what a person can do), which represents the patient’s ability to move, 
and is provided by supervised clinical tests such as the 6-min walking test 
 • Mobility perception (what a person thinks he or she does), which represents the patient’s 
subjective experience or perception of their own mobility, as provided through patient-
reported outcomes or clinician-assigned scores based on the patient’s answers to stan-
dardised questionnaires, such as MDS-UPDRS-II [30], the MSWS-12 [31] or the PPAC [32] 
 • Mobility performance (what a person actually does) which represents the duration, 
quality and intensity of the participant’s mobility as observed in real-world settings, 
during sufficiently long observational periods of time to be considered representative of 
daily life [33]. There are currently no accepted DMOs to quantify mobility performance
By taking this approach, DMOs collected continuously in the real-world complement 
existing mobility measures. Furthermore, the cohorts in Mobilise-D have very different tradi-
tional mobility outcomes, mobility difficulties and diverse disease trajectories, thereby 
allowing a comprehensive approach to quantify disability [34]. Ultimately, we see value in 
regulatory approval and health and technology assessment processes having a routine expec-
tation for an accurate measurement of mobility under real-world circumstances. Mobility per 
se is therefore a relevant concept of interest for our cohorts and forms the rationale for the 
work of the Mobilise-D consortium (Fig. 1).
Engaging the Regulators
The Mobilise-D consortium aims to present five different contexts of use for DMOs to 
quantify mobility performance. Four will address each individual cohort (PD, COPD, MS and 
PFF), and one will propose a disease-independent DMO. Regulatory requirements and 
processes for DMOs differ depending on the context of use in which the DMO is to be used. 
The focus of Mobilise-D is the “qualification of a new methodology,” which is where the DMO 
is used to inform the safety or efficacy of a new medical product, such as a new drug or digital 
therapeutic. 
There are different strategies to pursue the regulatory approval of DMOs. For example, a 
DMO can be proposed as a clinical outcome (and therefore a primary clinical end point) in its 
own right to quantify mobility performance. However, changes in mobility are often an 
indirect outcome of a drug being tested, not the primary target. A second strategy can therefore 
be adopted that is more conservative where mobility is not the target outcome for the drug 
being tested. Instead, mobility performance can be proposed as a secondary DMO (or digital 
mobility biomarker) to monitor the health condition or as a surrogate of an accepted clinical 
end point. This is especially relevant for some health conditions where mobility perception 
and/or capacity outcomes are already accepted for monitoring the state of the disease. This 
requires demonstration of both technical validity (to accurately measure) and clinical validity 
of the new biomarker by showing construct validity, predictive capacity and the ability to 
detect change. 
To our knowledge, there are currently only 2 cases where DMOs have been qualified for 
use in regulatory drug trials: the qualification opinion of the European Medicine Agency 
(EMA, EU Regulator) on the use of on-stride velocity 95th centile measured with wearable 
sensors as a secondary end point in Duchenne Muscular Dystrophy [35]; and the EMA Quali-
fication Opinion requested by the PROactive consortium on the use of DMOs by COPD 
specialists to assign a mobility-related clinician-reported outcome [36]. Both opinions are 
very narrow in scope in contrast to Mobilise-D which is targeting 4 different cohorts. When 
Trium Analysis Online GmbH submitted a letter of intent to the US regulator, the Food and 
Drugs Administration (FDA), proposing to use change in continuous real-world walking 
speed as a clinical end point in patients with MS, FDA advice suggested a dual element quali-
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fication process, which requires the need to demonstrate not only the validity of the DMO, but 
also the necessity of developing this new clinical end point, which is usually a much more 
ambitious goal [37].
Our long-term goal is the qualification of DMOs for two contexts of use. The first is to use 
the DMO to monitor the progression of the disease, where mobility performance is reduced 
with disease progression. The second is to use DMOs as surrogates of disease-specific 
secondary end points such as falls in PD and MS. Following the recommendations of EMA 
experts [13], we engaged in very early dialogue and adopted a staged approach to regulatory 
qualification. First, we received a positive qualification advice on the validation protocol we 
proposed for the use of a DMO as an additional digital monitoring biomarker to account for 
mobility performance in assessing the efficacy of new or existing treatments for PD patients, 
complementing those already in use that account only for patients’ perception of mobility and 
mobility capacity (see Viceconti et al. [38] for further detail). Second, we have recently 
requested a new qualification advice to find:
(i) the best DMO as a monitoring biomarker of mobility performance for each additional 
health condition (COPD, MS, and PFF);
(ii) the best DMO as a monitoring biomarker of mobility performance across all 4 health 
conditions;
(iii) the best DMO that can be used as a surrogate biomarker, to predict:
(a) for COPD: moderate-to-severe exacerbation requiring substantial changes in treatment 
and/or emergency room or hospital admission;
(b) for PFF: against admission to a long-term care facility or other form of assisted living 
setting;
(c) for MS and PD: against self-reported fall.
In all cases, the validation protocol we proposed includes an extensive technical vali-
dation with controlled experiments, and a clinical validation comprising the assessment of 
construct validity, predictive capacity and ability to detect change (described below). Key to 
this work was the need to engage in conversations with regulatory authorities at a very early 
stage, and this commenced at the start of Mobilise-D (Fig. 1) in parallel with the other activ-
ities of the consortium. 
Technical Validation: Does It Do What It Says on the Tin?
While objectively measuring real-world mobility is very attractive, it is far from simple 
or straightforward. Objectively measuring the ability to move about in the home and 
community requires clear definitions of the mobility feature to be measured and validation 
in the environment, context and population for which it is intended. This raises a number of 
significant challenges (see Del Din et al. [39] for a review) that are being addressed in Mobilise-
D so that a robust device-agnostic solution to accurately measure real-world mobility, device 
standards and protocol standardisation can be achieved (Fig. 1).
An essential requirement for validation of DMOs is to have clear definitions of the aspect 
of mobility to be measured to define the requirements for algorithms. Take, for example, real-
world walking speed as the DMO of interest. This requires that the precise start and end point 
of a “walking bout” is defined, and the timing and number of steps identified, from which the 
DMO is quantified. However, lack of consensus about what constitutes a walking bout, 
thresholds for bout length and the minimum number of steps required, has led to confusion 
and lack of consistency [39]. Brief pauses and resting periods between walking bouts [39–41] 
as well as turning [42, 43] driven by environmental contexts also affect the values of DMOs, 
especially when calculated as an average over a given walking bout [44, 45]. Mobilise-D has 
created a common language allowing algorithms to be developed according to a standard 
definition and parameters set consistently taking account of health condition and context. 
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Algorithmic requirements within Mobilise-D include the ability to calculate the DMOs of 
interest in different daily life contexts and for different patient groups, which is particularly 
challenging for a single sensor solution. Algorithms will have to account for the huge vari-
ability of signal features, associated with intrinsic gait factors (e.g., slow and impaired gait 
pattern with various characteristics), contextual factors (e.g., environment, usage of various 
walking aids) and variations in protocol (location of IMU). Associated algorithmic challenges 
are being tackled combining state-of-the-art signal processing, activity recognition and 
labelling approaches, for which published algorithms will be selected according to perfor-
mance on suitable existing data sets that have been made available to the consortium. Pre-
processing approaches are being used to tackle filtering and enhancement of walking step-
related features [46]. Gait sequence detection is based on combining adaptive thresholding, 
frequency analysis, wavelet analysis and machine learning techniques [47–50]. Labelling of 
steps and strides is exploring time-domain [51], frequency-domain [52] and template-
matching [53] approaches. All algorithms are being implemented using a sensor agnostic 
approach allowing them to be applied to new and existing data. Scripts are developed and 
fully documented on the GitLab platform, using an open-source license (GitLab Inc.). All the 
algorithms are run on the same standardised environment, and their executions are orches-
trated by the open source e-Science Central platform [54]. Once optimised on pre-existing 
data, algorithms will be tested on new data from an ad hoc technical validation study.
Validation of DMOs against a gold standard system to verify accuracy of algorithm perfor-
mance has to take context into account (real-world) [55]. This is relatively straightforward in 
the gait laboratory where sophisticated tools are available [56]. Observations conducted in a 
laboratory, however, are often limited to simple straight walking or to a range of activities 
mimicking daily life scenarios. Validation of a single sensor approach in an unsupervised, 
unprescribed context requires the development of ad hoc tools, which, to the best of the 
authors’ knowledge, have not been attempted to this extent. Mobilise-D will adopt a multi-
device and multisensor system approach that includes multiple IMUs located on different 
parts of the body, pressure insoles and distance sensors. This novel system, called INDIP 
(inertial module with distance sensors and pressure insoles) [57], is relatively unobtrusive 
and allows reference DMO data to be recorded in completely unsupervised conditions. The 
INDIP reference system is proprietary but for each component commercial alternatives are 
available. We use a commercial medical grade device for the centre of mass position 
(McRoberts, DynaPort MM+). Hardware and software requirements such as sampling rate 
will be made available allowing technology vendors to implement equivalent systems.
A technical validation study is under way in 120 participants (healthy older adults, PD, 
COPD, MS, PFF and chronic heart failure) recruited across 5 different sites in 3 European 
countries. Participants are required to undergo a series of observations under different condi-
tions:
(1) Prescribed walking tasks under laboratory conditions
(2) Simulated unprescribed tasks of daily living under laboratory conditions
(3) 2.5 h of continuous recording in the patient’s habitual environment (real world)
(4) 7 days of real-world recording
In all conditions, patients wear the commercial IMU at the centre of mass (McRoberts, 
DynaPort MM+) from which DMOs are derived. To assess precision and accuracy, DMOs 
derived from the novel algorithms are compared to: gold standards (from motion capture 
systems and INDIP) under laboratory conditions (1 and 2); the INDIP system (condition 3) in 
real-world conditions; and a smartphone app for contextualization including anonymised 
geolocation, indoors versus outdoors and type of terrain in the real world (conditions 3 and 
4). Condition 3 will also allow to label and contextualise DMOs. As a result of this validation 
study, the largest gold standard digital mobility database will be created to develop optimal 
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DMO algorithms and made available as a reference data set. Detailed algorithm development 
and benchmarking will be published elsewhere when complete.
Clinical Validation of DMOs: Global Mobility Assessment versus Disease Specificity? 
For DMOs to be useful, they need to (i) measure what they aim to measure (i.e., have 
construct validity), (ii) be related to something that is relevant for the patient (clinically 
meaningful), clinician or health service (i.e., have reliable predictive ability), and (iii) be able 
to measure change over time in response to changes in patient characteristics (i.e., sensitive 
to change). In Mobilise-D we will carry out a clinical validation study to demonstrate that 
selected DMOs measured with Mobilise-D algorithms have the above-mentioned properties 
when measured in real life. Clinical validation will be based on a multicentre observational 
study in 2,400 participants from PD, MS, COPD and PFF cohorts (600 per cohort) recruited in 
16 centres across Europe allowing diverse health care systems, geographical areas and 
different socio-economic regions to be represented. Participants will be followed for 24 
months over 5 visits. All participants will wear the commercial IMU (McRoberts, DynaPort 
MM+) which has been validated in the technical validation study for a full 7 days. A detailed 
protocol and training package is under development to ensure standardised device placement 
to optimise reliability of data collection.
One important complication is that mobility characteristics and clinical course differ by 
disease and disease state/stage. It is therefore likely that normative DMOs and the association 
between DMOs and clinical outcomes are different across diseases. Evaluating DMOs across 
different disease conditions under a single study protocol is therefore challenging. To address 
this challenge, we will use 2 approaches to test construct validity, predictive ability and sensi-
tivity to change: 
(i) Using disease-specific outcomes, to provide insight into the best DMO for each disease, 
and where to focus potential future interventions such as the Expanded Disability Status 
Scale for MS [58] and the Movement Disorders Society – Unified Parkinson’s Disease 
Rating Scale [30] 
(ii) Using a disease-independent outcome, such as the Later Life Functional Disability Index 
[59] and the Short Physical Performance Battery [25], to inform about the properties of 
DMOs across a wide range of clinical populations with distinct mobility impairment 
patterns
Aggregation of continuous data into a single outcome measure or DMO presents a unique 
challenge. Continuous monitoring is ideal when one wants to measure an event that takes 
place at a given point of time (e.g., a sudden arrhythmia) or count the number of events during 
a given period of time (e.g., number of apnoeic episodes during sleep time or number of steps 
during waking hours). However, summarising mobility characteristics is more difficult. For 
example, whilst there is agreement that walking speed is a relevant DMO driving interest in 
assessing “real-world” walking speed, the question remains – what is real world? The key is 
in defining the level and criteria for data aggregation.
Algorithms that have validated the assessment of walking speed do so at the walking bout 
(episode of walking of a given minimum number of steps) level [39, 44]. Walking speed at the 
walking bout level is complex because people have many bouts during the day of different 
durations [44] (from a few seconds for a bout inside the house to several hours for an outdoor 
stroll) and different characteristics (flat surface/uphill/downhill, indoor/outdoor, linear/
curvilinear, etc.). Criteria to select walking bouts included in daily or weekly summary 
measures must be defined, for example, only those walking bouts lasting at least x minutes, 
only those that are outdoors, and so on. Finally, given the variability in walking speed across 
walking bouts in the same person, one needs to decide which statistic best summarises “real-
world” walking speed. For example, if mean or median values are taken, the result could be 
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influenced by few walking bouts with extreme walking speed. If maximum values are taken, 
one could argue this is not a measure of walking speed but of exercise capacity. These aspects 
are being evaluated in Mobilise-D together with other considerations including whether 
these aspects are similar for all DMOs across cohorts.
Data, Data, Data: Processing, Standards, Security, Ethics
The Mobilise-D research programme presents a significant data management challenge, 
and work to address this was started from the outset (Fig. 1). Multidimensional data will be 
captured across 16 different sites in 10 different countries over multiple measurement 
periods. In the clinical validation phase alone, we will potentially capture over 2 million hours 
of sensor data from 2,400 study participants. This requires a standardised approach to 
process the data (capture, transfer, ingest, integrate, store) prior to analysis (Fig. 2). Stan-
dardization must adhere to relevant legal frameworks, and implement appropriate data 
access and governance models. The data acquired in Mobilise-D will be made available as 
open data for the research community beyond the term of the research programme, whilst 
adhering to EU data privacy requirements. 
A guiding principle for Mobilise-D is that the highest standards of data integrity are 
adhered to in all activities. The Mobilise-D consortium has therefore adopted ALCOA+ data 
integrity principles [60] requiring that all data records are attributable, contemporaneous, 
original, accurate, complete, consistent, available and enduring. Practically this means that all 
original source data must be integrated and maintained indefinitely on a secure platform in 
a manner that preserves the data and privacy rights of the study participants. A rigorous 
monitoring and quality assurance process ensures data records are accurate and complete 
and is underpinned by a comprehensive education and support programme for clinical inves-
tigators and study participants. 
To ensure we meet data privacy and security requirements we are adhering to General 
Data Protection regulation [61] and directive 2006/24/EC [62] and have implemented a 
series of privacy-by-design measures to protect the privacy and data rights of study partici-
pants throughout the process. All data will be integrated, managed and stored using unique 
identifier codes. Personal identifiable data will be managed locally and will not be transferred 








































Data integrity Open data
Source Type
Fig. 2. Mobilise-D data management platform summary. PROs, patient-reported outcomes; COAs, clinical 
outcome assessments.
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Central, a scalable cloud-based platform to support secure storage, analysis and sharing of 
multimodal data [54] that is implemented on Amazon Web Services. All data will be encrypted 
in transit and at rest. Flat files will be stored in S3 buckets which are encrypted using AES-256 
encryption. Amazon relational databases will also be encrypted using AES-256. A data ware-
house model enables flexibility in application of appropriate analytical workflows.
An access and governance model ensures data are available to appropriate stakehold- 
ers when needed during Mobilise-D. Finally, steps to make the data set open and available to 
the wider research community will ensure ongoing development opportunity beyond Mobi- 
lise-D. 
Engaging Stakeholders
An endeavour with the scope and ambition of Mobilise-D invariably draws attention from 
many interested parties, collectively called stakeholders. Centre stage stakeholders for 
Mobilise-D are the patients themselves, both current and future, who suffer from mobility 
loss. From here the circle widens to caregivers, users and providers of health and social care 
services, patient organisations, industry and academia, as well as the wider public. To ensure 
meaningful, continued and embedded involvement and engagement of all these stakeholders, 
Mobilise-D has developed a Patient and Public Involvement and Engagement strategy that 
details our vision, framework and guiding principles (Fig. 3) to support the integration of 
patient and public engagement and involvement across the entire process of research, devel-
opment and validation, and engagement with regulatory agencies, health technology 
assessment bodies, ethics committees, research organisations and pharmaceutical industries 
and associations. From the outset, Mobilise-D has engaged the public through frequent 
updates about the work of the consortium (Fig. 1). Going forward, patients are directly 
involved in Mobilise-D as participants in our technical and clinical validation studies, and 










findings of Mobilise-DFig. 3. Mobilise-D principles for 
patient and public engagement, 
following definitions from NIHR | 
INVOLVE (https://www.invo.org.
uk/).
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consultation, collaboration and coproduction of, for example, participant-facing documents 
and dissemination materials. Mobilise-D has structured patient and public engagement 
around 5 areas of engagement: (1) discussions at the overall project level, focused on general 
Mobilise-D approaches and strategies; (2) discussions about digital health technology in 
general and digital mobility assessment and outcomes in particular; (3) discussions about the 
usability, value and impact of DMOs in daily life and how the latter can contribute to improved 
patient care; (4) consultation around health technology assessment and regulatory accep-
tance of DMOs for clinical use; and (5) involvement in promotion activities about the impact 
and benefits of Mobilise-D results.
Conclusion
So what is next? Mobilise-D describes a roadmap outlining the effort needed to bring 
digital biomarkers from concept to approval. When combined with continuous learning, 
disease modelling and enhanced methods for data transfer, we predict the benefits, scaling 
up and implementation will continue to be refined and accelerate the adoption of digital 
outcomes as routine in research. Similar efforts directed to routine health care will ensure 
these benefits can be realised for patients with transformation of patient management. Ulti-
mately, the knowledge gained from continuous real-world digital monitoring will provide 
insights previously unavailable and lead to innovation in therapeutic development and 
personalised health care.
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